To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can be combined with other agents to benefit patients.
Checkpoint inhibitors continue to show promise in the treatment of patients with non-small cell lung cancer (NSCLC), but researchers are now exploring the efficacy of these agents when combined with radiation therapy (RT).
Justin Chura, MD, discusses his initial approach to treating ovarian cancer. Anya Khomenko, survivor of ovarian cancer, advises patients on how to become educated on new therapeutic options and prepare for follow-up appointments.